Pharming Group NV

Pharming Group NV

Pharming Group NV

Overview
Date Founded

1988

Headquarters

Darwinweg 24,Leiden, Zuid-Holland 2333 CR

Type of Company

Public

Employees (Worldwide)

150

Industries

Other Business & Consulting Services
Hospitals & Patient Services
Biotechnology

Company Description

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.

Contact Data
Trying to get in touch with decision makers at Pharming Group NV? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Executive Director & Chief Executive Officer

Chief Financial Officer

Chief Operations Officer

Chief Ethics & Compliance Officer

Chief Medical Officer

Chief Commercial Officer & General Manager Americas

Chairman of the Board of Supervisory Directors

Vice Chairman of the Board of Supervisory Directors

Chairman of the Board of Supervisory Directors

Senior Regulatory Affairs Specialist

Supervisory Board

President & Chief Executive Officer at eGenesis, Inc.

Associate Partner at NPEX BV

Former Chief Executive Officer at KuDOS Pharmaceuticals Ltd.

Paths to Pharming Group NV
Potential Connections via
Relationship Science
You
Pharming Group NV
Owners & Shareholders
Details Hidden

Founded in 1998, JW Asset Management LLC is a hedge fund manager located in New York City.

Details Hidden

HP is an alternative investment manager specializing in healthcare investments. The firm invests globally in equity, their assets being almost entirely invested in the US.They follow a long/short equity strategy and may occasionally engage in shareholder activism.HP's investment process targets under-researched firms in the pharmaceutical, medical technology, biotechnology and healthcare service sectors. They favor micro-, small- and mid-cap companies. Their investment philosophy consists in leveraging their healthcare expertise to identify companies for which market value largely underestimates or overestimates intrinsic value and growth potential.HP's investment process is bottom-up and based on in-house research supplemented with input from sector specialists. The firm relies on the expertise of medical experts including academics. Non-core functions are outsourced.

Details Hidden

NHP Asset Management AG is a private company headquartered in Zurich, Switzerland, that provides investment advice. The firm was founded in 2013 by Walter Nötzli, he has been the CEO since then.

Transaction Advisors
Investment Advisor

Advised onPharming Group NV purchases ProBio, Inc.

Legal Advisor

Advised onPharming Group NV purchases ProBio, Inc.

Clients

Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique protein purification technology. Kamada´s product line consists of more than 10 injectable pharmaceutical products which are marketed in more than 15 countries worldwide. The Company's pharmaceuticals are produced in its state-of-the-art, cGMP-compliant, FDA-approved, large scale production facility. Kamada’s flagship product is Glassia®; an FDA approved intravenous (IV) Alpha-1 Antitrypsin (AAT) protein, for the treatment of AAT Deficiency. Glassia® is a high purity, ready to use and stabilizer free augmentation treatment .Kamada has a strategic agreement with Baxter for US marketing, distribution and licensing of Glassia®. Kamada’s second generation AAT product is an inhaled (IH) version. This product is already in advanced stages of clinical development for the treatment of AAT Deficiency. Other potential indications for AAT (IV or IH) include bronchiectasis, cystic fibrosis, COPD as well as type-1 diabetes for which the Company started a clinical trial. Sided to its capabilities to manufacture specialty proteins, Kamada has developed a platform technology for the production of specific immunoglobulins (IgGs). Kamada´s unique know-how and capabilities enable it to seek for new business opportunities and offer a wide scope of pharma-oriented services, including: R&D of new biopharmaceuticals, large scale production of high quality biopharmaceuticals, formulation and aseptic filling, registration and marketing. Over the years Kamada has established its presence in the pharma industry worldwide. Kamada’s mission is to develop, manufacture and provide high quality, specialty pharmaceuticals to patients, in order to support better quality of life and save lives. Founded in 1990, Kamada successfully completed an Initial Public Offering in 2005.The company is traded at the Tel Aviv Stock Exchange (KMDA). Kamada's headquarters is located in the Weizmann Science Park in Nes Ziona, Israel

Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceutical. The firm focuses on the hematology and immunology therapeutic areas. It also offers specialty treatments in the area of genetics and metabolism. The company was founded in 2001 and is headquartered in Solna, Sweden.

China National Pharmaceutical Group Co., Ltd. engages in the distribution, retail, scientific research and manufacture of healthcare products. The company is headquartered in Beijing, China.

Key Stats and Financials As of 2020
Market Capitalization
$825M
Total Enterprise Value
$934M
Earnings Per Share
$0.06
EBITDAMargin
38.89%
Enterprise Value / Sales
4.48x
Enterprise Value EBITDAOperating
11.53x
TEVNet Income
25.2x
Debt TEV
0.16x
Three Year Compounded Annual Growth Rate Of Revenue
27.49%
Revenue
$208M
Net Profit
$37.1M
EBITDA
$81.1M
Total Debt
$148M
Total Equity
$168M
Investments
Details Hidden

DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders.DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands.

Details Hidden
Investors
Details Hidden

Resona Capital is an active manager which seeks to invest in early stage venture firms with innovative ideas. The firm utilizes the Resona Bank group network to provide hands-on investment for investee companies operating in wide range of sectors. The firm generally makes their investment decisions in one month.

Suppliers
Sanofi Industrial Machinery & Manufacturing | Paris, France

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

BioConnection BV Holding Companies | Oss, Netherlands

BioConnection BV manufactures and develops injectable pharmaceutical products. Its services include fill & finish, freeze drying, clinical trial material services, project management and consultancy services. The company was founded in 2005 and is headquartered in Oss, the Netherlands.

Novartis AG Medical Support Services | Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Pharming Group NV. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Pharming Group NV's profile does not indicate a business or promotional relationship of any kind between RelSci and Pharming Group NV.